Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: A critical review

Arthritis Research and Therapy

Volumn 11, Issue SUPPL. 1, 2009, Pages

  Rubbert Roth, Andrea ^a   Finckh, Axel ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ATLIZUMAB; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

APPLICATION SITE REACTION; BASAL CELL CARCINOMA; CLINICAL TRIAL; DEMYELINATING DISEASE; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FUNCTIONAL STATUS; HEART FAILURE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INFECTION; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; NEOPLASM; OPPORTUNISTIC INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOLID TUMOR; SURVIVAL; T CELL LYMPHOMA; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; DRUG ANTAGONISM; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 64549161956     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2666     Document Type: Review

References (72)

1. Lee DM Weinblatt ME Rheumatoid arthritis Lancet 2001, 358:903-911 10.1016/S0140-6736(01)06075-5 11567728
2. Gabriel SE Crowson CS Kremers HM Doran MF Turesson C O'Fallon WM Matteson EL Survival in rheumatoid arthritis: A population-based analysis of trends over 40 years Arthritis Rheum 2003, 48:54-58 10.1002/ art.10705 12528103
3. Mikuls TR Saag KG Criswell LA Merlino LA Kaslow RA Shelton BJ Cerhan JR Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: Results from the Iowa Women's Health Study Ann Rheum Dis 2002, 61:994-999 1753931 12379522 10.1136/ard.61.11.994
4. Pincus T Kavanaugh A Sokka T Benefit/risk of therapies for rheumatoid arthritis: Underestimation of the 'side effects' or risks of RA leads to underestimation of the benefit/risk of therapies Clin Exp Rheumatol 2004, 22(suppl 35):S2-S11
5. Emery P Genovese MC Kavanaugh AF Cohen SB Perez JL Sasso EH Adalimumab plus methotrexate results in less frequent and less severe radiographic progression than methotrexate alone at all levels of clinical response in early rheumatoid arthritis [abstract] Ann Rheum Dis 2006, 65(suppl II):88
6. Smolen JS Heijde van der DM St Clair EW Emery P Bathon JM Keystone E Maini RN Kalden JR Schiff M Baker D Han C Han J Bala M Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial Arthritis Rheum 2006, 54:702-710 10.1002/art.21678 16508926
7. Strand V Cohen S Schiff M Weaver A Fleischmann R Cannon G Fox R Moreland L Olsen N Furst D Caldwell J Kaine J Sharp J Hurley F Loew-Friedrich I Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group Arch Intern Med 1999, 159:2542-2550 10.1001/archinte.159.21.2542 10573044
8. Bathon JM Martin RW Fleischmann RM Tesser JR Schiff MH Keystone EC Genovese MC Wasko MC Moreland LW Weaver AL Markenson J Finck BK A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl J Med 2000, 343:1586-1593 10.1056/ NEJM200011303432201 11096165
9. Breedveld FC Weisman MH Kavanaugh AF Cohen SB Pavelka K van Vollenhoven R Sharp J Perez JL Spencer-Green GT The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 2006, 54:26-37 10.1002/art.21519 16385520
10. Klareskog L Heijde van der D de Jager JP Gough A Kalden J Malaise M Mola EM Pavelka K Sany J Settas L Wajdula J Pedersen R Fatenejad S Sanda M Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: Double-blind randomised controlled trial Lancet 2004, 363:675-681 10.1016/S0140-6736(04)15640-7 15001324
11. Lipsky PE Heijde van der DM St Clair EW Furst DE Breedveld FC Kalden JR Smolen JS Weisman M Emery P Feldmann M Harriman GR Maini RN Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group N Engl J Med 2000, 343:1594-1602 10.1056/NEJM200011303432202 11096166
12. Maini R St Clair EW Breedveld F Furst D Kalden J Weisman M Smolen J Emery P Harriman G Feldmann M Lipsky P Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group Lancet 1999, 354:1932-1939 10.1016/S0140-6736(99)05246-0 10622295
13. Weinblatt ME Kremer JM Bankhurst AD Bulpitt KJ Fleischmann RM Fox RI Jackson CG Lange M Burge DJ A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 1999, 340:253-259 10.1056/ NEJM199901283400401 9920948
14. Weinblatt ME Keystone EC Furst DE Moreland LW Weisman MH Birbara CA Teoh LA Fischkoff SA Chartash EK Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial Arthritis Rheum 2003, 48:35-45 10.1002/art.10697 12528101
15. Smolen J Kay J Doyle MK Landewe R Matteson EL Wollenhaupt J Gaylis N Murphy F Neal J Zamani O Zhou Y Visvanathan S Hsia EC Rahman MU Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): Results of the randomized double-blind, placebo-c (sic) [abstract] Ann Rheum Dis 2008, 67(suppl II):50
16. Tracey D Klareskog L Sasso EH Salfeld JG Tak PP Tumor necrosis factor antagonist mechanisms of action: A comprehensive review Pharmacol Ther 2008, 117:244-279 10.1016/j.pharmthera.2007.10.001 18155297
17. Landewe R Smolen J Keystone EC van Vollenhoven R Heijde van der D Radiographic inhibition of progression of structural damage: Results from the RAPID 2 trial Ann Rheum Dis 2008, 67(suppl II):321
18. Heijde van der D Weinblatt M Landewe R Goel N Wells F Fleischmann RM Early inhibition of progression of structural damage in certolizumab pegol-treated patients: 16-week efficacy results from RAPID Ann Rheum Dis 2008, 67(suppl II):51
19. Finckh A Simard JF Gabay C Guerne PA Evidence for differential acquired drug resistance to anti-TNF agents in rheumatoid arthritis Ann Rheum Dis 2008, 67:746-752
20. Radstake T Svenson M Eijsbouts AM Hoogen van den FHJ Enevold C van Riel P Bendtzen K Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis Ann Rheum Dis 2008
21. Kamal KM Madhavan SS Hornsby JA Miller LA Kavookjian J Scott V Use of tumor necrosis factor inhibitors in rheumatoid arthritis: A national survey of practicing United States rheumatologists Joint Bone Spine 2006, 73:718-724 10.1016/j.jbspin.2006.05.002 16997599
22. Summary of product characteristics: MabThera 100 mg and 500 mg concentrate for solution for infusion http://emc.medicines.org.uk/emc/ assets/c/html/DisplayDoc.asp?DocumentID=2570
23. Emery P Keystone E Cantagrel A van Vollenhoven R Sanchez A Alecock E Lee J Kremer J Tocilizumab (TCZ) significantly improves disease outcomes in patients with rheumatoid arthritis whose anti-TNF therapy failed: The RADIATE study [abstract] Ann Rheum Dis 2008, 67(suppl II):127
24. van Vollenhoven RF Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue Ann Rheum Dis 2007, 66:849-851 10.1136/ard.2007.069872 17576784
25. Bombardieri S Ruiz AA Fardellone P Geusens P McKenna F Unnebrink K Oezer U Kary S Kupper H Burmester GR Research in Active Rheumatoid Arthritis (ReAct) Study Group: Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice Rheumatology (Oxford) 2007, 46:1191-1199 10.1093/ rheumatology/kem091 17504821
26. Keystone EC Perruquet JL Lidham RW Stein B Pellar JS Xia HA Eickenhorst T Switching anti-TNF therapy: Real world outcome of patients with rheumatoid arthritis who failed either infliximab or etanercept of treatment and switched to another TNF inhibitor [abstract] Arthritis Rheum 2004, 50(suppl):S400-S401
27. Kristensen LE Saxne T Geborek P The LUNDEX, a new index of drug efficacy in clinical practice: Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden Arthritis Rheum 2006, 54:600-606 10.1002/ art.21570 16447237
28. Kristensen LE Saxne T Geborek P Switching between anti-TNF therapies does not affect level of adherence to therapy in rheumatoid arthritis but response rates seem to decline. [abstract] Ann Rheum Dis 2006, 65(suppl II):327
29. Navarro F Gomez-Reino JJ Marsal S EULAR response in clinical practice in RA patients treated with one, two or three anti-TNF alpha agents: results of an observational, prospective, cohort study in Spain [abstract] Arthritis Rheum 2006, 54(suppl II):S384
30. Yazici Y Erkan D Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann Rheum Dis 2004, 63:607-608 1754974 15082503
31. Karlsson JA Kristensen LE Kapetanovic MC Gulfe A Saxne T Geborek P Treatment response to a second or third TNF-inhibitor in RA: Results from the South Swedish Arthritis Treatment Group Register Rheumatology (Oxford) 2008, 47:507-513 10.1093/rheumatology/ken034 18304941
32. Furst DE Gaylis N Bray V Olech E Yocum D Ritter J Weisman M Wallace D Crues J Khanna D Eckel G Yeilding N Callegari P Visvanathan S Rojas J Hegedus R George L Mamun K Gilmer K Troum O Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: The OPPOSITE study Ann Rheum Dis 2007, 66:893-899 10.1136/ard.2006.068304 17412737
33. Hyrich KL Lunt M Watson KD Symmons DPM Silman AJ Furstenberg CT Outcomes after switching from one anti-tumor necrosis factor α agent to a second anti-tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study Arthritis Rheum 2007, 56:13-20 10.1002/art.22331 17195186
34. Blom M Kievit W Fransen J Kuper IH Laar van der M de Rooj D de Gendt C Jansen TL Effectiveness of a switch to a second anti-TNF-α in primary nonresponders, secondary nonresponders and failure due to adverse events [abstract] Arthritis Rheum 2007, 56(suppl):S165
35. Gullick N Da Silva C Kirkham B Failure of adalimumab in patients with rheumatoid arthritis [abstract] Arthritis Rheum 2007, 56(suppl):S183
36. Buch MH Bingham SJ Bryer D Emery P Long-term infliximab treatment in rheumatoid arthritis: Subsequent outcome of initial responders Rheumatology (Oxford) 2007, 46:1153-1156 10.1093/rheumatology/kem075 17478470
37. Gomez-Reino JJ Carmona L Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period Arthritis Res Ther 2006, 8:R29 1526564 16507128 10.1186/ ar1881
38. Kishimoto M Greenberg J Abramson SB Harrington T Olenginski TP Kafka SP Reed G Hinkle K Kremer J Cohen SB Drug survival time on anti-TNF agents: does prior anti-TNF use influence RA outcomes? [Abstract] Arthritis Rheum 2005, 52(suppl):S347
39. Genovese MC Becker JC Schiff M Luggen M Sherrer Y Kremer J Birbara C Box J Natarajan K Nuamah I Li T Aranda R Hagerty DT Dougados M Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition N Engl J Med 2005, 353:1114-1123 10.1056/NEJMoa050524 16162882
40. Cohen SB Emery P Greenwald MW Dougados M Furie RA Genovese MC Keystone EC Loveless JE Burmester GR Cravets MW Hessey EW Shaw T Totoritis MC Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, Phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 2006, 54:2793-2806 10.1002/ art.22025 16947627
41. Kremer JM Tony HP Genovese MC Tak PP Luggen M Bombardieri S Hessey E Safa-Leathers S Repeat treatment with rituximab in active RA patients: long-term efficacy in patients with one versus two or more prior TNF inhibitors Ann Rheum Dis 2007, 66(suppl): 432
42. Kremer JM Tony HP Tak PP Luggen M Mariette X Hessey E McCabe D Safa-Leathers S Efficacy of rituximab in active RA patients with an inadequate response to one or more TNF inhibitors Ann Rheum Dis 2006, 65(suppl II):326
43. van Vollenhoven R Cullinane Carli C Augustsson J Klareskog L Experience with rituximab in the treatment of rheumatoid arthritis (RA): Results from the Sture Registry [abstract] Ann Rheum Dis 2008, 67(suppl II):340
44. Keystone E Fleischmann RM Emery P Chubick A Dougados M Baldassare AR Bathon JM Hessey E Hagerty D Cooper S Repeated treatment courses of rituximab in rheumatoid arthritis: Sustained efficacy in patients with an inadequate response to one or more TNF inhibitors [abstract] Ann Rheum Dis 2007, 66(suppl II):432
45. Genovese MC Schiff M Luggen M Becker JC Aranda R McCann T Schmidely N Le Bars M Dougados M Sustained efficacy and safety through 2 years in patients with rheumatoid arthritis (RA) in the long-term extension of the ATTAIN trial [abstract] Arthritis Rheum 2006, 54(suppl):S244
46. Hyrich K Lunt M Dixon WG Watson KD Symmons DPM Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug Rheumatology (Oxford) 2008, 47:1000-1005 2430221 18420660 10.1093/rheumatology/ken127
47. Aletaha D Smolen J Ward MM Measuring function in rheumatoid arthritis: identifying reversible and irreversible components Arthritis Rheum 2008, 54:2784-2792 10.1002/art.22052
48. Keystone E Burmester GR Furie R Loveless JE Emery P Kremer J Tak PP Broder MS Yu E Cravets M Magrini F Jost F Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy Arthritis Rheum 2008, 59:785-793 10.1002/art.23715 18512710
49. Keystone EC Emery P Peterfy CG Tak PP Cohen S Genovese MC Dougados M Burmester GR Greenwald M Kvien TK Williams S Hagerty D Cravets MW Shaw T Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumour necrosis factor inhibitor therapies Ann Rheum Dis 2009, 68:216-221 10.1136/ard.2007.085787 18388156
50. Cohen S Keystone E Genovese M Emery P Peterfy C Tak PP Cravets M Shaw T Hagerty D Continued inhibition of structural damage in rheumatoid arthritis patients treated with rituximab at 2 years: Reflex study [abstract] Ann Rheum Dis 2008, 67(suppl II):189
51. Keystone EC Emery P Peterfy CG Tak PP Cohen SB Genovese MC Williams S Cravets MW Hagerty D Shaw T Inhibition of radiographic progression with rituximab is not dependent on clinical efficacy: Results from a study in rheumatoid arthritis patients with an inadequate response to one or more TNF inhibitors (REFLEX) [abstract] Ann Rheum Dis 2007, 66(suppl II):431
52. Smolen JS Han C Bala M Maini RN Kalden JR Heijde van der D Breedveld FC Furst DE Lipsky PE Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study Arthritis Rheum 2005, 52:1020-1030 10.1002/art.20982 15818697
53. Kremer JM Genant HK Moreland LW Russell AS Emery P Abud-Mendoza C Szechiñski J Li T Ge Z Becker JC Westhovens R Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: A randomized trial Ann Intern Med 2006, 144:865-876 16785475
54. Finckh A Ciurea A Brulhart L Kyburz D Mõller B Dehler S Revaz S Dudler J Gabay C O'Brien S B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents Arthritis Rheum 2007, 56:1417-1423 10.1002/ art.22520 17469098
55. Finckh A Ciurea A Brulhart L Moeller B Walker UA Courvoisier D Kyburz D Gabay C Which subgroup of rheumatoid arthritis patients benefit most from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agents? [Abstract] Ann Rheum Dis 2008, 67(suppl II):127
56. Venkatachalam S Roskell S Suchitra R Price T Mulherin D Sheeran T Rituximab may be more effective than switching to an alternative TNF inhibitor in rheumatoid arthritis patients who have failed other TNF inhibitors Rheumatology (Oxford) 2008, 47:iI28 10.1093/rheumatology/ kem513
57. Hochberg MC Lebwohl MG Plevy SE Hobbs KF Yocum DE The benefit/risk profile of TNF-blocking agents: Findings of a consensus panel Semin Arthritis Rheum 2005, 34:819-836 10.1016/j.semarthrit.2004.11.006 15942917
58. Imperato AK Bingham CO III Abramson SB Overview of benefit/risk of biological agents Clin Exp Rheumatol 2004, 22(suppl 35):S108-S114
59. Wolfe F Michaud K Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum 2004, 50:1740-1751 10.1002/art.20311 15188349
60. Wolfe F Michaud K Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study Arthritis Rheum 2007, 56:2886-2895 10.1002/art.22864 17729297
61. Montori V Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 2006, 295:2275-2285 10.1001/jama.295.19.2275 16705109
62. Furst DE Breedveld FC Kalden JR Smolen JS Burmester GR Sieper J Emery P Keystone EC Schiff MH Mease P van Riel PL Fleischmann R Weisman MH Weinblatt ME Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 Ann Rheum Dis 2007, 66(suppl 3):iIi2-iii22 10.1136/ard.2007.081430 17934088
63. Mackey AC Green L Liang LC Dinndorf P Avigan M Hepato-splenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease J Pediatr Gastroenterol Nutr 2007, 44:265-267 17255842
64. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group Etanercept plus standard therapy for Wegener's granulomatosis N Engl J Med 2002, 61:351-361
65. Askling J Fored CM Brandt L Baecklund E Bertilsson L Feltelius N Coster L Geborek P Jacobsson LT Lindblad S Lysholm J Rantapää-Dahlqvist S Saxne T van Vollenhoven RF Klareskog L Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists Ann Rheum Dis 2007, 66:1339-1344 10.1136/ard.2006.062760 17261532
66. Dixon W Watson K Hyrich K Lunt M Silman A Symmons D The incidence of serious infections is not increased in patients with rheumatoid arthritis treated with anti-TNF drugs compared to those treated with traditional DMARDs: Results from a national prospective study [abstract] Arthritis Rheum 2006, 52(suppl):S738
67. Listing J Strangfeld A Kary S Rau R von HU Stoyanova-Scholz M GromnicaIhle E Antoni C Herzer P Kekow J Schneider M Zink A Infections in patients with rheumatoid arthritis treated with biologic agents Arthritis Rheum 2005, 52:3403-3412 10.1002/art.21386 16255017
68. van Vollenhoven RF Emery P Bingham CO III Keystone E Greenwald M Moreland LW Sweetser M Rowe K Wagner B Magrini F Extended follow-up of the long-term safety of rituximab in rheumatoid arthritis [abstract] Arthritis Rheum 2007, 56(suppl):S147-S148
69. Genovese M Emery P Ruderman E Keystone E Furst D van Vollenhoven R Sweetser M Magrini F Tindall E Shaw T Yocum D Immunoglobulin levels and infection rates in patients with rheumatoid arthritis treated with repeated courses of rituximab [abstract] Arthritis Rheum 2007, 56(suppl):S149
70. Simon TA Smitten AL Boodhoo T Askling J Franklin J Lecaille D Wolfe F Observed and expected malignancies in the abat-acept clinical development program: An epidemiological assessment [abstract] Ann Rheum Dis 2006, 65(suppl II):489
71. Orencia® [abatacept] prescribing information http://www.bms.com/cgi-bin/anybin.pl?sql=select%20PPI%20from%20 TB_PRODUCT_PPI%20where%20PPI_SEQ=111&key=PPI
72. Genovese MC Breedveld FC Emery P Moreland LW Keystone EC Matteson EL Baptiste Y Burke L Reiss W Sweetser M Shaw T Safety of TNF inhibitors and non-biologic DMARDs in rheumatoid arthritis patients previously treated with rituximab [abstract] Arthritis Rheum 2007, 56(suppl):S150